- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06548113
Sensory Synchronized Imaging and Neuromodulation
May 7, 2026 updated by: VA Office of Research and Development
Investigation of Sensory Synchronized Human Brain Imaging and Neuromodulation
The purpose of this research study is to better understand the relationship between the type of brain stimulation used and how it changes brain activity in adult military Veterans.
The goal is to use this understanding to develop new, personalized brain stimulation.
The investigators evaluate brain changes from different types of transcranial magnetic brain stimulation (TMS).
Study Overview
Study Type
Interventional
Enrollment (Estimated)
250
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jessica M Ross, PhD
- Phone Number: (530) 902-2450
- Email: jessica.ross1@va.gov
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304-1207
- VA Palo Alto Health Care System, Palo Alto, CA
-
Contact:
- Jessica M Ross, PhD
- Phone Number: 530-902-2450
- Email: jessica.ross1@va.gov
-
Principal Investigator:
- Jessica M Ross, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Men and women, ages 18 years and up
- English speaking
- Military Veterans
Exclusion Criteria:
- Those with a contraindication for MRIs (e.g. implanted metal)
- History of head trauma with loss of consciousness
- History of seizures or on medications that substantially reduce seizure threshold
- Neurological or uncontrolled medical disease
- Active substance abuse
- Currently pregnant or breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Standard TMS
A series of standard TMS protocols will be delivered to determine target engagement compared to seTMS.
TMS will be delivered using neuro-navigation based on participant's own MRI images.
Intensity will be set to 120% of the participant's motor threshold.
Participants will be monitored during the session for adverse events and/or side effects.
|
transcranial magnetic brain stimulation
|
|
Active Comparator: Sensory-entrained TMS (seTMS)
Sensory entrained TMS (seTMS) is a combination of music and TMS to align brain oscillations and enhance the effects of TMS.
seTMS will be delivered to determine target engagement to noninvasive seTMS brain stimulation compared to standard TMS.
TMS will be delivered using neuro-navigation based on participant's own MRI images.
Intensity will be set to 120% of the participant's motor threshold.
Participants will be monitored during the session for adverse events and/or side effects.
|
transcranial magnetic brain stimulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Transcranial Magnetic Stimulation (TMS) / Electroencephalography (EEG) change
Time Frame: 45 minutes
|
Change in the TMS-EEG measure will be assessed before, during, and after each TMS session.
Specifically, the difference in size of the evoked response after a single TMS pulse in the frontoparietal region will be quantified in microVolts and compared between standard TMS and sensory-entrained TMS (se-TMS).
|
45 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jessica M Ross, PhD, VA Palo Alto Health Care System, Palo Alto, CA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
October 1, 2029
Study Completion (Estimated)
October 1, 2029
Study Registration Dates
First Submitted
August 1, 2024
First Submitted That Met QC Criteria
August 8, 2024
First Posted (Actual)
August 12, 2024
Study Record Updates
Last Update Posted (Actual)
May 11, 2026
Last Update Submitted That Met QC Criteria
May 7, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MHBC-011-24F
- 76106 (Other Identifier: VA Palo Alto Health Care System)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Gang WangWest China Hospital; The First Hospital of Hebei Medical University; Tianjin... and other collaboratorsRecruitingMajor Depressive Disorder (MDD) | Depression - Major Depressive DisorderChina
-
Brian MickeyNational Institute of Mental Health (NIMH)RecruitingMajor Depressive Episode | Depression - Major Depressive Disorder | Treatment-Resistant Major Depressive DisorderUnited States
-
Unity Health TorontoUniversity of Toronto; Toronto Metropolitan UniversityRecruitingMajor Depressive Disorder (MDD) | Major Depressive Episode | Treatment-Resistant Major Depressive DisorderCanada
-
Stanford UniversityNational Institute of Mental Health (NIMH)Recruiting
-
TakedaRecruitingMajor Depressive DisorderJapan
-
Neurocrine BiosciencesRecruitingMajor Depressive DisorderSpain, Serbia, United States, Bulgaria, Canada, Estonia, Italy, Poland, Taiwan, Australia, South Korea
-
Luye Pharma Group Ltd.Enrolling by invitationMajor Depressive DisorderChina
-
NeuroQore Inc.Makromed Inc.Enrolling by invitationMajor Depressive DisorderUnited States
-
The Royal Ottawa Mental Health CentreNot yet recruitingDepression | Major Depressive Disorder (MDD) | Depressive Episode | Depression - Major Depressive DisorderCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
Clinical Trials on TMS
-
Hartford HospitalRecruiting
-
Carilion ClinicUnknown
-
Emory UniversityCompleted
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedExecutive FunctionUnited States
-
Bayside HealthNational Health and Medical Research Council, AustraliaCompletedMajor Depressive DisorderAustralia
-
Bayside HealthCompleted
-
Auburn UniversityNational Institute on Drug Abuse (NIDA); Society of Addiction PsychologyRecruiting
-
Centre Hospitalier St AnneRecruitingTreatment Resistant SchizophreniaFrance
-
Mclean HospitalMassachusetts General HospitalCompletedSchizophrenia | Schizoaffective Disorder | Bipolar Disorder IUnited States
-
NYU Langone HealthWithdrawn